Column Group IV GP, LP bought $1.0M of EIKN
owner at Eikon Therapeutics, Inc.. 89,200 shares at an average of $11.56, traded Sep 3, 2026, filed Sep 8, 2026.
Score components
- +12Role10% owner
- +25Trade size$1.0M at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-385268, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 3, 2026 | POpen-market purchase Common Stockindirect: See footnote | +89,200 | $11.56 | $1.0M | 89,200 | 35 d ago |
Related signals
Other insiders at Eikon Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 67Notable | Eikon Therapeutics, Inc. | Column Group IV GP, LP owner | $38M 2,117,760 shares | +74% | |
| 47Moderate | Eikon Therapeutics, Inc. | Foresite Capital Management IV, LLC owner | $1000k 55,555 shares | +4% | |
| 63Notable | Eikon Therapeutics, Inc. | Josh Wolfe director, owner | $5.0M 277,776 shares | - | |
| 63Notable | Eikon Therapeutics, Inc. | Josh Wolfe director, owner | $5.0M 277,776 shares | - | |
| 63Notable | Eikon Therapeutics, Inc. | Kenneth C Frazier director | $2.0M 111,111 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.